What is bioAffinity Technologies?
bioAffinity Technologies, Inc. is dedicated to pioneering non-invasive diagnostic tests for the early detection of lung cancer and other pulmonary diseases. Established in 2014 and headquartered in San Antonio, Texas, the company's flagship offering, CyPath lung, aims to revolutionize early-stage lung cancer identification. The company's focus on developing accessible and accurate diagnostic tools positions it within the rapidly evolving MedTech and diagnostics sector, addressing a critical unmet need in public health.
How much funding has bioAffinity Technologies raised?
bioAffinity Technologies has raised a total of $13.3M across 6 funding rounds:
Series A
$4M
Debt
$150K
Debt
$5M
Debt
$212K
Share Placement
$2.5M
Share Placement
$1.4M
Series A (2017): $4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2020): $5M supported by Undisclosed
Debt (2021): $212K featuring PPP
Share Placement (2024): $2.5M backed by WallachBeth Capital
Share Placement (2025): $1.4M, investors not publicly disclosed
Key Investors in bioAffinity Technologies
WallachBeth Capital
WallachBeth Capital is a leading provider of institutional execution services, specializing in unconflicted advice and intelligent trading solutions. The company offers a comprehensive range of services including execution, consulting, and capital markets support.
What's next for bioAffinity Technologies?
With the recent influx of major strategic investment, bioAffinity Technologies is poised for accelerated growth and product development. This substantial capital infusion, totaling $1.4M, is expected to fuel advancements in their diagnostic platform, potentially expanding its application to a wider range of diseases. The company's trajectory suggests a move towards scaling its operations and increasing market penetration, solidifying its position as a key player in the early disease detection landscape. Further strategic partnerships and clinical validation are anticipated as the company leverages this financing to achieve its long-term objectives.
See full bioAffinity Technologies company page
